Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …

Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative
review aimed to highlight the current evidence and recommendations of antiplatelet therapy …

Objective Antiplatelet medications are increasingly being used for primary and secondary
prevention of ischemic attacks owing to the increasing prevalence of ischemic stroke …

Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include
clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and …

Single antiplatelet therapy represents the cornerstone of thrombosis prevention in
atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of …

Acute ischemic stroke is a leading cause of death and major disability worldwide.
Approximately 50% of ischemic strokes are caused by atherothrombotic occlusion of the …

The Roundtable of Academia and Industry for Stroke Prevention conference convened a
panel to discuss important topics to advance the treatment and prevention of large-vessel …

There is considerable inter-individual variability in the effectiveness and safety of
pharmaceutical interventions. This phenomenon can be attributed to a multitude of factors; …

Background Trimethylamine N‐oxide (TMAO) contributes to cardiovascular disease through
its prothrombotic, proatherothrombotic, and proinflammatory effects. We aimed to evaluate …

Background Strokes significantly impair quality of life and incur high economic and societal
burdens. The triglyceride and glucose (TyG) index is a biochemical marker of insulin …